CHD4 and breast cancer: Abolition of CHD4 impairs the recruitment of HDAC1 to the p21 promoter, resulting in the upregulation of anti-proliferative effector P21 (a cyclin-dependent kinase inhibitor protein), suggesting that CHD4 is a potential therapeutic target in breast cancer [78].